Inotuzumab Ozogamicin is named as a drug or biological intervention in 4 clinical trials in our China and Ireland trial registers, 2 of which are recruiting. Lead sponsors include Mats Heyman (1), Sheng-Li Xue, MD (1) and Ruijin Hospital (1). Registered phases: Phase 2, Phase 3 and Observational. Conditions studied include Leukemia, Acute Lymphoblastic; ALL; MRD-positive.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (ClinicalTrials.gov ↗) Leukemia, Acute Lymphoblastic |
Phase 3 | Recruiting |
| NCT05940961 | Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL (ClinicalTrials.gov ↗) ALL, MRD-positive, Hematopoietic Stem Cell Transplantation |
Phase 2 | Recruiting |
| NCT05456698 | Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy (ClinicalTrials.gov ↗) Acute Lymphocytic Leukemia |
Phase 2 | Active, closed |
| NCT07238907 | A Multi-center Retrospective Study of INO Treating B-ALL (ClinicalTrials.gov ↗) Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL), Inotuzumab Ozogamicin |
Observational | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Leukemia, Acute Lymphoblastic | 1 |
| ALL | 1 |
| MRD-positive | 1 |
| Hematopoietic Stem Cell Transplantation | 1 |
| Acute Lymphoblastic Leukaemia | 1 |
| Acute Lymphoblastic Leukaemias (ALL) | 1 |
| Inotuzumab Ozogamicin | 1 |
| Venetoclax | 1 |
| Acute Lymphocytic Leukemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Mats Heyman | 1 |
| Sheng-Li Xue, MD | 1 |
| Ruijin Hospital | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Register | Inotuzumab Ozogamicin trials |
|---|---|
| Clinical trials in China | 3 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Inotuzumab Ozogamicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Inotuzumab Ozogamicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.